TP53 and cancer: In our cohort, the majority of tumors showed homozygous mutations (9 of 14), which is concordant with data obtained across all kinds of cancers, where it has been shown that the loss of the wild-type TP53 allele, or second hit, occurs in approximately 90% of cases [19].